Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

110 <strong>Solvay</strong> Global Annual Report 2005 Consolidated data per share In EUR 2002 2003 2004 2005 Capital and reserves after distribution* 32,34 32,23 34,92 45,46 Cash fl ow 12,95 9,91 12,00 15,42 REBITDA 16,69 13,16 13,88 16,13 Net income 5,59 4,78 5,92 9,51 Net income (excluding discontinued operations) 5,64 4,83 5,12 3,77 Number of shares (in thousands) at December 31 84 600 84 610 84 623 84 696 Number of shares (in thousands) for calculating IFRS earnings per share 83 059 82 748 82 521 83 021 Diluted net income 5,58 4,78 5,90 9,46 Diluted net income (excluding discontinued operations) Average number of shares (in thousands) for calculating IFRS diluted earnings per share 5,63 4,82 5,11 3,75 83 208 82 776 82 751 83 491 Gross dividend 2,40 2,40 2,53 2,67 Net dividend 1,80 1,80 1,90 2,00 Highest price 78 69,3 83,9 104,1 Lowest price 58,7 47,6 64,1 79,95 Price at December 31 65,7 68,75 81 93,1 Price/earnings at December 31 11,9 14,4 13,7 9,8 Net dividend yield 2,7% 2,6% 2,3% 2,1% Gross dividend yield 3,7% 3,5% 3,1% 2,9% Annual volume (thousands of shares) 25 672 27 068 27 710 44 181 Annual volume (EUR million) 1 790 1 667 2000 4011 Market capitalization at December 31 (EUR billion) 5,6 5,8 6,9 7,9 Velocity (%) 30,9 32,3 31,5 53,3 Velocity adjusted by Free Float (73%) (in%) 41,2 44,2 43 ,1 71,1
Shareholders’ Diary – May 9, 2006: Annual General Meeting and Extraordinary General Meeting (14.00) and announcement of three months 2006 earnings – May 16, 2006: payment of the balance of the 2005 dividend (coupon no. 78) – July 28, 2006: announcement of six months 2006 earnings – October 27, 2006: announcement of nine months 2006 earnings – December 15, 2006: announcement of the interim dividend for 2006 (payable in January 2007, coupon no. 79)
Page 1 and 2:
Driven by the future Growth, Compet
Page 3 and 4:
Highlights January 2005 Solvay fi n
Page 5 and 6:
Activities Group sales 2005 = EUR 8
Page 7 and 8:
Our Vision - Independent industrial
Page 9 and 10:
here to stay, in our view irreversi
Page 11 and 12:
Board of Directors and Corporate Go
Page 13 and 14:
4 Executive Committee and General M
Page 15 and 16:
Such a strategy is possible only wi
Page 17 and 18:
Specialities Solvay Specialties fro
Page 19 and 20:
Key fi gures [EUR million] Pharmace
Page 21 and 22:
Cardiometabolic Cardiovascular dise
Page 23 and 24:
Cardiometabolics Fenofi brate, TRIC
Page 25 and 26:
“ DUODOPA® entered Solvay’s pr
Page 27 and 28:
Pharmaceuticals Sector Therapeutic
Page 29 and 30:
Key fi gures [EUR million] Chemical
Page 31 and 32:
Growth To speed up its growth, the
Page 33 and 34:
Initiatives have also been launched
Page 35 and 36:
“ The ‘Soil Remediation Reagent
Page 37 and 38:
Key fi gures [EUR million] Plastics
Page 39 and 40:
Innovation “Twin-Sheet Blow Mould
Page 41 and 42:
Plastics 37 Solvay Global Annual Re
Page 43 and 44:
which it was able to take advantage
Page 45 and 46:
New Business Development Priority t
Page 47 and 48:
Meeting The Science Days organized
Page 49 and 50:
Human Resources The Group’s fi ve
Page 51 and 52:
“ At the end of this seminar, all
Page 53 and 54:
Sustainable Development 2005 saw th
Page 55 and 56:
Accident frequency rate Persons wor
Page 57 and 58:
Management Report New records for S
Page 59 and 60:
Expenditure on the future by Sector
Page 61 and 62:
Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92: Analysis of total fi nancial debt b
Page 93 and 94: In this way, at the end of 2005, th
Page 95 and 96: The following amounts relating to J
Page 97 and 98: PORTUGAL Fournier Farmaceutica Port
Page 99 and 100: List of fully consolidated Group co
Page 101 and 102: Solvay Salz Holding GmbH, Hannover
Page 103 and 104: CANADA Fournier Pharma, Inc., Montr
Page 105 and 106: GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108: Summary fi nancial statements of So
Page 109 and 110: Statutory auditor’s report to the
Page 111 and 112: The Solvay share compared with the
Page 113: Contacts: The Investor Relations Te
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?